• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CG Oncology Inc.

    7/22/24 4:35:57 PM ET
    $CGON
    Get the next $CGON alert in real time by email
    SC 13G 1 d840327dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. )*

     

     

    CG Oncology, Inc.

    (Name of Issuer)

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

    156944100

    (CUSIP Number)

    June 30, 2024**

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **

    We are early adopting the revised filing deadline under the new Rule 13d-1(d) which went effective on February 5, 2024 and will require compliance starting on September 30, 2024.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     Unique Diamond Investments Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     British Virgin Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     1,011,192(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     1,011,192(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,011,192(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.5%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 1,011,192 shares of the Issuer’s Common Stock (as defined in item 2(d)) held directly by Unique Diamond Investments Limited.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Healthcare Fund, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     1,011,192(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     1,011,192(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,011,192(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.5%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Represents 1,011,192 shares of the Issuer’s Common Stock held directly by Unique Diamond Investments Limited. Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Capital Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     1,011,192(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     1,011,192(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,011,192(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.5%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents 1,011,192 shares of the Issuer’s Common Stock held directly by Unique Diamond Investments Limited. Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and may be deemed to have voting, investment and dispositive power with respect to these securities.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Capital Holding Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     1,011,192(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     1,011,192(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,011,192(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.5%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents 1,011,192 shares of the Issuer’s Common Stock held directly by Unique Diamond Investments Limited. Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     Charming Jade Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     British Virgin Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     3,930,176(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     3,930,176(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,930,176(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     5.9%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Healthcare Fund II, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     3,930,176(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     3,930,176(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,930,176(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     5.9%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

    (1)

    Represents 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Capital II Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     3,930,176(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     3,930,176(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,930,176(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     5.9%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and may be deemed to have voting, investment and dispositive power with respect to these securities.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     ORI Holding II Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     3,930,176(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     3,930,176(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,930,176(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     5.9%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     Healthcare Seed Limited

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     British Virgin Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     4,941,368(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     4,941,368(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,941,368(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     7.4%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Represents the sum of (i) 1,011,192 shares of the Issuer’s Common Stock held directly by Unique Diamond Investments Limited, and (ii) 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited. Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc. Each of ORI Capital Holding Inc. and ORI Holding II Inc. is a wholly owned subsidiary of Healthcare Seed Limited.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    CUSIP No. 156944100

     

     1.   

     Names of Reporting Persons

     

     SONG, Hong Fang

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☐

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Hong Kong

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     Sole Voting Power

     

     5,555,296(1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     5,555,296(1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,555,296(1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     8.3%(2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Represents the sum of (i) 1,011,192 shares of the Issuer’s Common Stock held directly by Unique Diamond Investments Limited, (ii) 3,930,176 shares of the Issuer’s Common Stock held directly by Charming Jade Limited, and (iii) 613,928 shares of the Issuer’s Common Stock held directly by Ms. Song. Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc. Each of ORI Capital Holding Inc. and ORI Holding II Inc. is a wholly owned subsidiary of Healthcare Seed Limited. Ms. Song is the sole owner of Healthcare Seed Limited.

    (2)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.


    Item 1.

    Issuer

     

      (a)

    Name of Issuer:

    CG Oncology, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    400 Spectrum Center Drive, Suite 2040, Irvine, California, 92618

     

    Item 2.

    Filing Person

     

      (a)

    Name of Persons Filing

    Unique Diamond Investments Limited

    Charming Jade Limited

    ORI Healthcare Fund, L.P.

    ORI Healthcare Fund II, L.P.

    ORI Capital Inc.

    ORI Capital II Inc.

    ORI Capital Holding Inc.

    ORI Holding II Inc.

    Healthcare Seed Limited

    SONG, Hong Fang

    Unique Diamond Investments Limited is a wholly owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and a wholly owned subsidiary of ORI Capital Holding Inc. Charming Jade Limited is a wholly owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and a wholly owned subsidiary of ORI Holding II Inc. Each of ORI Capital Holding Inc. and ORI Holding II Inc. is a wholly owned subsidiary of Healthcare Seed Limited. Ms. Song is the sole owner of Healthcare Seed Limited.

    Each of the foregoing parties is referred to as a “Reporting Person” and collectively, as the “Reporting Persons.”

    The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this statement as Exhibit 99.1.

     

      (b)

    Address of Principal Business Office, or, if none, Residence:

    The principal business office of each of the Reporting Persons is C/O Room Nos., 4727-34, Sun Hung Kai Centre, 30 Harbour Road.

     

      (c)

    Citizenship

    Unique Diamond Investments Limited: British Virgin Islands

    Charming Jade Limited: British Virgin Islands

    ORI Healthcare Fund, L.P.: Cayman Islands

    ORI Healthcare Fund II, L.P.: Cayman Islands

    ORI Capital Inc.: Cayman Islands

    ORI Capital II Inc.: Cayman Islands

    ORI Capital Holding Inc.: Cayman Islands

    ORI Holding II Inc.: Cayman Islands

    Healthcare Seed Limited: British Virgin Islands

    SONG, Hong Fang: Hong Kong

     

      (d)

    Title of Class of Securities:

    Common stock, $0.0001 par value per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    156944100


    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

     

    Reporting Person    Amount
    beneficially
    owned
        

    Percentage

    of class (1)

        Sole power
    to vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole power
    to dispose or
    to direct the
    disposition
    of
        

    Shared power

    to dispose or

    to direct the

    disposition of

     

    Unique Diamond Investments Limited

         1,011,192        1.5 %      1,011,192        0        1,011,192        0  

    ORI Healthcare Fund, L.P.

         1,011,192        1.5 %      1,011,192        0        1,011,192        0  

    ORI Capital Inc.

         1,011,192        1.5 %      1,011,192        0        1,011,192        0  

    ORI Capital Holding Inc.

         1,011,192        1.5 %      1,011,192        0        1,011,192        0  

    Charming Jade Limited

         3,930,176        5.9 %      3,930,176        0        3,930,176        0  

    ORI Healthcare Fund II, L.P.

         3,930,176        5.9 %      3,930,176        0        3,930,176        0  

    ORI Capital II Inc.

         3,930,176        5.9 %      3,930,176        0        3,930,176        0  

    ORI Holding II Inc.

         3,930,176        5.9 %      3,930,176        0        3,930,176        0  

    Healthcare Seed Limited

         4,941,368        7.4 %      4,941,368        0        4,941,368        0  

    SONG, Hong Fang

         5,555,296        8.3 %      5,555,296        0        5,555,296        0  

     

    (1)

    This calculation is based on 66,640,150 shares of Common Stock outstanding as of May 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: July 22, 2024

     

    Unique Diamond Investments Limited
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director
    Charming Jade Limited
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director

     

    ORI Healthcare Fund, L.P.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director
    ORI Healthcare Fund II, L.P.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director of General Partner

     

    ORI Capital Inc.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director
    ORI Capital II Inc.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director


    ORI Capital Holding Inc.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director
    ORI Holding II Inc.
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director

     

    Healthcare Seed Limited
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang
    Title:   Director

     

    SONG, Hong Fang
    By:   /s/ SONG, Hong Fang
    Name:   SONG, Hong Fang


    EXHIBIT INDEX

     

    Exhibit     
    99.1    Joint Filing Agreement

     

    Get the next $CGON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    6/28/2024$65.00Buy
    BofA Securities
    2/20/2024$75.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

      IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximate

      5/15/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical bi

      5/13/25 8:00:00 AM ET
      $CGON
    • SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

      - Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced t

      5/1/25 8:00:00 AM ET
      $CGON

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on CG Oncology with a new price target

      Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

      5/2/25 8:14:21 AM ET
      $CGON
    • Scotiabank initiated coverage on CG Oncology with a new price target

      Scotiabank initiated coverage of CG Oncology with a rating of Sector Perform and set a new price target of $23.00

      4/16/25 8:09:10 AM ET
      $CGON
    • TD Cowen initiated coverage on CG Oncology

      TD Cowen initiated coverage of CG Oncology with a rating of Buy

      1/7/25 7:46:13 AM ET
      $CGON

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

      4/A - CG Oncology, Inc. (0001991792) (Issuer)

      4/9/24 7:08:23 PM ET
      $CGON

    $CGON
    SEC Filings

    See more

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

      SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      5/15/25 4:32:25 PM ET
      $CGON
    • SEC Form 10-Q filed by CG Oncology Inc.

      10-Q - CG Oncology, Inc. (0001991792) (Filer)

      5/13/25 8:30:21 AM ET
      $CGON
    • CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      5/13/25 8:15:10 AM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/12/24 2:30:47 PM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/4/24 10:22:51 AM ET
      $CGON
    • SEC Form SC 13G filed by CG Oncology Inc.

      SC 13G - CG Oncology, Inc. (0001991792) (Subject)

      7/22/24 4:35:57 PM ET
      $CGON

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,000 worth of shares (1,000 units at $28.00) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      5/22/25 4:15:05 PM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $30,760 worth of shares (1,000 units at $30.76) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/29/25 4:15:03 PM ET
      $CGON
    • SEC Form 4 filed by Chief Executive Officer Kuan Arthur

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:18 PM ET
      $CGON

    $CGON
    Financials

    Live finance-specific insights

    See more
    • CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

      - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

      4/26/25 4:10:03 PM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

      4/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

      - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

      3/28/25 7:00:00 AM ET
      $CGON